Catalyst Pharmaceuticals Acquired by Angelini Pharma | Healthcare M&A Deal

Angelini Pharma has completed the acquisition of Catalyst Pharmaceuticals, a pharmacy business in the United States, for $4B. Catalyst Pharmaceuticals develops and commercializes rare disease therapies, including Firdapse for a neuromuscular disorder, supporting specialized patient access in the healthcare market. Angelini Pharma acquisitions expand its neurological medicines portfolio through this pharmacy acquisition, strengthening its global growth strategy. The platform acquisition is a strategic acquisition announced as part of broader healthcare M&A, with deal size over $100M and an expected closing timeline to be confirmed.